BeyondSpring (NASDAQ:BYSI) Receives "Sell (D)" Rating from Weiss Ratings

Key Points

• BeyondSpring's stock has been restated with a "Sell (D)" rating by Weiss Ratings, indicating unfavorable outlook for the company.
• The stock price for BeyondSpring (NASDAQ:BYSI) was trading at $2.01, with a trading volume of 18,946 shares, below its average volume.
• Geode Capital Management raised its stake in BeyondSpring by 951.4% in the second quarter, owning approximately 0.64% of the company, highlighting growing institutional interest.

BeyondSpring (NASDAQ:BYSI - Get Free Report)'s stock had its "sell (d)" rating restated by Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

BeyondSpring Stock Performance

BYSI stock traded down $0.01 during midday trading on Friday, hitting $2.01. The company's stock had a trading volume of 18,946 shares, compared to its average volume of 37,215. BeyondSpring has a 52-week low of $0.98 and a 52-week high of $3.44. The firm has a 50-day simple moving average of $1.81 and a 200-day simple moving average of $1.90.

BeyondSpring (NASDAQ:BYSI - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.04) EPS for the quarter.

Institutional Investors Weigh In On BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC grew its position in BeyondSpring Inc. (NASDAQ:BYSI - Free Report) by 951.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 256,212 shares of the company's stock after purchasing an additional 231,844 shares during the quarter. Geode Capital Management LLC owned approximately 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. 40.29% of the stock is currently owned by institutional investors and hedge funds.

About BeyondSpring

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.